[{"id":"608c0d3a-2362-4472-ad82-9dd04e9005a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03909971","created_at":"2021-01-18T19:14:43.723Z","updated_at":"2024-07-02T16:35:18.353Z","phase":"Phase 2","brief_title":"A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China","source_id_and_acronym":"NCT03909971","lead_sponsor":"Pfizer","biomarkers":" EML4","pipe":" | ","alterations":" ALK positive • EML4-ALK fusion • ALK fusion","tags":["EML4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • EML4-ALK fusion • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 109","initiation":"Initiation: 04/28/2019","start_date":" 04/28/2019","primary_txt":" Primary completion: 08/10/2020","primary_completion_date":" 08/10/2020","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-02-21"},{"id":"06550efe-3df8-4523-a393-27c6fed5ccbc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04499794","created_at":"2021-01-18T21:33:22.286Z","updated_at":"2024-07-02T16:36:42.346Z","phase":"","brief_title":"The Study of Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic Monitoring","source_id_and_acronym":"NCT04499794","lead_sponsor":"Chinese Academy of Medical Sciences","biomarkers":" EML4","pipe":" | ","alterations":" EML4-ALK fusion • ALK fusion","tags":["EML4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EML4-ALK fusion • ALK fusion"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 08/01/2020","start_date":" 08/01/2020","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2020-08-05"},{"id":"11f2b7a9-d56e-449d-b5fb-ad3668a3f5c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01803282","created_at":"2021-01-18T07:59:16.880Z","updated_at":"2024-07-02T16:36:44.574Z","phase":"Phase 1","brief_title":"Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT01803282","lead_sponsor":"Gilead Sciences","biomarkers":" HER-2 • ALK • EML4","pipe":" | ","alterations":" EGFR mutation • HER-2 negative • EML4-ALK fusion • ALK fusion • ALK translocation","tags":["HER-2 • ALK • EML4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 negative • EML4-ALK fusion • ALK fusion • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium • andecaliximab (GS-5745)"],"overall_status":"Completed","enrollment":" Enrollment 236","initiation":"Initiation: 03/29/2013","start_date":" 03/29/2013","primary_txt":" Primary completion: 04/23/2019","primary_completion_date":" 04/23/2019","study_txt":" Completion: 04/23/2019","study_completion_date":" 04/23/2019","last_update_posted":"2020-06-02"},{"id":"11a75896-ed72-4de4-bf64-92a7e752fb1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03158324","created_at":"2021-01-18T15:34:16.926Z","updated_at":"2024-07-02T16:37:21.037Z","phase":"Phase 2a","brief_title":"Phase IIa Dose-Expansion and Biomarker Study of OPB-111077","source_id_and_acronym":"NCT03158324","lead_sponsor":"National University Hospital, Singapore","biomarkers":" EGFR • BRAF • ALK • EML4 • SIRT1","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • ALK positive • EML4-ALK fusion • ALK fusion • ALK mutation • RET mutation","tags":["EGFR • BRAF • ALK • EML4 • SIRT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • ALK positive • EML4-ALK fusion • ALK fusion • ALK mutation • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e OPB-111077"],"overall_status":"Unknown status","enrollment":" Enrollment 52","initiation":"Initiation: 05/22/2017","start_date":" 05/22/2017","primary_txt":" Primary completion: 05/22/2020","primary_completion_date":" 05/22/2020","study_txt":" Completion: 11/30/2020","study_completion_date":" 11/30/2020","last_update_posted":"2017-06-15"},{"id":"93ec58dd-b458-4f90-b4ff-d9adbbac82ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT00932893","created_at":"2021-01-17T17:10:30.301Z","updated_at":"2024-07-02T16:37:26.804Z","phase":"Phase 3","brief_title":"An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene","source_id_and_acronym":"NCT00932893","lead_sponsor":"Pfizer","biomarkers":" ALK • MET • EML4 • HGF","pipe":" | ","alterations":" ALK positive • EML4-ALK fusion • ALK fusion","tags":["ALK • MET • EML4 • HGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • EML4-ALK fusion • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • docetaxel • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 347","initiation":"Initiation: 09/01/2009","start_date":" 09/01/2009","primary_txt":" Primary completion: 03/01/2012","primary_completion_date":" 03/01/2012","study_txt":" Completion: 01/01/2016","study_completion_date":" 01/01/2016","last_update_posted":"2017-01-02"}]